期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 35, 期 3, 页码 282-287出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2009.10.023
关键词
Fusidic acid; Staphylococci; Surveillance; North America
资金
- Cempra Pharmaceuticals (Chapel Hill, NC)
- AB BIODISK
- Abbott
- API
- Arpida
- Astellas
- AstraZeneca
- Avexa
- Bayer
- bioMerieux
- Cadence
- Cempra
- Cerexa
- Chiron
- Cornerstone
- Cubist
- Daiichi
- Elan
- Elanco
- Enanta
- GlaxoSmithKline
- Johnson & Johnson (Ortho McNeil)
- Merck
- Novartis
- Optimer
- Ordway
- Osmotics
- Pacific Beach, Peninsula
- Pfizer
- Protez
- Replidyne
- Schering-Plough
- Sequoia
- Shionogi
- Theravance
- TREK Diagnostics
- ViroPharma
- Wyeth
We evaluated the antimicrobial activity of fusidic acid (CEM-102) against 1140 clinical strains of Gram-positive bacteria obtained from patients with bacteraemia or skin and skin-structure infections collected in more than 30 medical centres in the USA and Canada over a 10-year period (1997-2006). Fusidic acid was very active against meticillin-susceptible Staphylococcus aureus (MSSA), meticillin-resistant S. aureus (MRSA) and coagulase-negative staphylococci (CoNS), with MIC90 values (minimum inhibitory concentration encompassing 90% of isolates tested) at 0.12 mu g/mL for US strains of MSSA, MRSA and CoNS and 0.25 mu g/mL for Canadian strains of MSSA and MRSA. A progressive increase in fusidic acid resistance was observed among Canadian strains of S. aureus (12.2% in 2005-2006) and among Canadian strains of CoNS. In contrast, no fusidic acid resistance was detected among US S. aureus strains and only 1.5% among CoNS. Fusidic acid was equally active against community-acquired MRSA and linezolid-resistant staphylococci. Fusidic acid exhibited equal or greater potency against staphylococci compared with vancomycin, daptomycin and linezolid. (C) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据